carfilzomib: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
carfilzomib: clinical details
Prescribing considerations
- Treatment must be supervised by a physician experienced in anticancer therapy; review the product information for every combination component.
- Assess cardiovascular risk, control hypertension and individualise fluid management.
- Assess thromboembolic and tumour-lysis risk; consider indicated prophylactic measures.
- Screen all patients for hepatitis B and involve an appropriate specialist when serology is positive.
- Consider antiviral prophylaxis against herpes-zoster reactivation.
- Use particular caution with significant heart disease, uncontrolled hypertension or arrhythmia, renal or hepatic impairment, high tumour burden and previous thrombosis.
Contraindications and cautions
- Hypersensitivity to carfilzomib or an excipient.
- Breastfeeding.
- Apply additional contraindications belonging to combination medicines.
Monitoring
- Full blood count, particularly neutrophils and platelets.
- Blood pressure, cardiovascular symptoms, fluid balance and volume overload.
- Renal function, electrolytes and evidence of tumour lysis.
- Liver enzymes and bilirubin.
- Hepatitis B status and, when positive, evidence of reactivation.
- New pulmonary, neurological, cognitive or behavioural symptoms.
Clinical pharmacology
Carfilzomib selectively and irreversibly inhibits the chymotrypsin-like activity of the 20S proteasome. It is rapidly and extensively metabolised mainly through peptidase cleavage and epoxide hydrolysis; cytochrome P450 metabolism is minor, and systemic clearance is rapid.
Formulation and product differences
- Single-use, preservative-free powder requiring aseptic reconstitution before intravenous infusion.
- Vial presentations differ in sodium and betadex sulfobutyl ether sodium content.
- The reconstituted solution must not be mixed or co-infused with other medicinal products.
carfilzomib interactions
The cancer team should review all prescribed, non-prescription and herbal products. Relevant interactions include:
Oral or thrombosis-associated hormonal contraceptives
Contraceptive effectiveness may be reduced, while some hormonal methods may add to clot risk; an alternative effective method is required.
Digoxin or colchicine
Carfilzomib may affect P-glycoprotein transport, so additional caution and clinical monitoring may be needed.
Erythropoiesis-stimulating treatments or hormone replacement therapy
These may add to venous-thrombosis risk, requiring individual assessment.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.